Cancer is one of the most expensive diseases to treat, with projected costs during 2010 expected to approach $264 billion. On average, an oncologist spends $2.3 million annually on such products. The cancer arena continues to grow, and drug spending in this therapeutic field is forecast to increase 12-14% in 2010.
The amount of oncology drugs in the overall pharmaceutical/biotechnology product pipeline is more than twice the total of any other therapeutic area. Company developers as well as clinicians are searching for better approaches to target tumors. For instance, a new generation of cancer therapeutics are using the immune system. Many emerging cancer treatments have the potential to become blockbuster brands.
Pipelines from the top 15 therapeutic areas are presented in order determined by the total number of products awaiting approval and in clinical trials in the United States.
The lists for each therapeutic area detail:
-Phase of development